Shares of Alkermes Plc (NASDAQ: ALKS) are trading up more than 40 percent in Thursday’s after-hours session, after the company announced positive topline results from its late-stage clinical study of ALKS 5461 for the treatment of depression.
According to data out of FORWARD-5, the company’s third phase 3 efficacy study, ALKS 5461 considerably reduced the symptoms seen in patients with major depression disorder, compared to a placebo.
Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!
Based on these results, the company said it plans to “move forward rapidly to meet with the FDA to determine the appropriate next steps toward a regulatory submission for ALKS 5461.”
“ALKS 5461 is being developed as an add-on treatment for patients with depression not controlled by currently approved drugs. The pill had been touted by Alkermes as a potential blockbuster and an important growth driver based on promising results from a mid-stage study,” TheStreet's Adam Feuerstein explained.
Shares traded recently at $61.28, up 41 percent.
Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.